Mallia Therapeutics and Northway Biotech Announce Partnership for the Manufacturing of Soluble CD83 Protein for Hair Loss Treatment
2025年2月4日 - 7:00PM
JCN Newswire
Mallia Therapeutics ("Mallia"), a biopharmaceutical company
developing novel treatments for hair loss, and Northway Biotech
("NBT"), a biologics Contract Development and Manufacturing
Organization (CDMO), have announced a partnership for the
development of the production process and manufacturing of Mallia's
soluble CD83 protein (sCD83), a treatment aimed at promoting hair
follicle formation and growth.
Under the agreement, Northway Biotech will leverage its expertise
in biologics manufacturing to develop the production process for
the recombinant sCD83 protein for large-scale production, utilizing
the Pichia pastoris expression system. This collaboration includes
the development of analytical methods, technology scale-up, and the
manufacturing of a cGMP Drug Substance.
Dr. Manfred Groeppel, co-founder and Managing Director of Mallia
Therapeutics, said: "With this partnership, we are advancing the
development of sCD83 to turn our research into a scalable treatment
for patients."
"Interestingly, sCD83's mode of action induces both the formation
of new hair follicles and thus hair growth, and has the potential
to redefine treatment approaches for hormone-induced androgenetic
alopecia as well as immune-mediated alopecia areata," emphasizes
Prof. Dr. Alexander Steinkasserer, co-founder and Managing Director
of Mallia. "By developing a robust production process, we are
ensuring the quality required for future clinical as well as
commercial applications."
Prof. Vladas Algirdas Bumelis, CEO and Chairman of Northway
Biotech, expressed, "We are excited to be working with Mallia on
developing the manufacturing process of sCD83. Our priority is to
ensure the highest manufacturing standards and maintain clear, open
communication as we collaborate every step of the way."
"Mallia's team and their innovative solution make this project
particularly appealing to us given its huge potential and the large
need from people all over the world for treatment. The strong and
transparent collaboration we have established allows us to support
Mallia with confidence as we move forward together quickly,"added
Andre Markmann, PhD, VP of Business Development at Northway
Biotech.
About Mallia Therapeutics GmbH
Mallia Therapeutics GmbH is a biopharmaceutical company focused on
developing novel treatments for patients suffering from hair loss.
The Company was founded in 2023 in Erlangen, Germany, and is led by
an experienced management team and worldwide leading experts in the
field of CD83, with more than 60 CD83-related publications and 20
years of experience in the field.
With sCD83, a potential treatment for hair loss in preclinical
development, Mallia aims to enter the multi-billion-dollar alopecia
market and provide patients with a safe and effective topical
treatment.
Connect with us on LinkedIn or find out more here:
https://mallia-therapeutics.com/
About Northway Biotech
Northway Biotech is a leading contract development and
manufacturing organization (CDMO) supporting customers worldwide.
Its highly experienced and professional team executes projects at
every stage, from cell line construction and process development to
cGMP manufacturing of biopharmaceutical products. The company's
extensive expertise and vertically integrated service offering
enable rapid execution of multiple projects from its
state-of-the-art GMP facilities while ensuring full process and
product compliance at all stages of research, development, and
commercial manufacturing. Northway Biotech is a privately owned
company founded in 2004 and operates locations in Vilnius,
Lithuania; London, United Kingdom; and Waltham, MA, USA. For more
information, please visit www.northwaybiotech.com.
Mallia Therapeutics Contact:
Mallia Therapeutics GmbH
info@mallia-therapeutics.com
International Media Contact:
MC Services AG
Dr. Regina Lutz / Katja Arnold
Tel.: +49 (0)89 210 228 0
E-Mail: mallia-therapeutics@mc-services.eu
Contact Information
Vladas Bumelis
CEO and Chairman of the Board
vladas.bumelis@northwaybiotech.com
SOURCE: Northway Biotech
Copyright 2025 JCN Newswire . All rights reserved.